JP2012519168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519168A5 JP2012519168A5 JP2011552066A JP2011552066A JP2012519168A5 JP 2012519168 A5 JP2012519168 A5 JP 2012519168A5 JP 2011552066 A JP2011552066 A JP 2011552066A JP 2011552066 A JP2011552066 A JP 2011552066A JP 2012519168 A5 JP2012519168 A5 JP 2012519168A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- cancer
- group
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15562409P | 2009-02-26 | 2009-02-26 | |
| US61/155,624 | 2009-02-26 | ||
| PCT/US2010/024340 WO2010099003A2 (en) | 2009-02-26 | 2010-02-16 | Compositions and methods for visualizing and eliminating cancer stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108085A Division JP2014156484A (ja) | 2009-02-26 | 2014-05-26 | がん幹細胞を可視化・排除するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519168A JP2012519168A (ja) | 2012-08-23 |
| JP2012519168A5 true JP2012519168A5 (https=) | 2013-03-28 |
| JP5963443B2 JP5963443B2 (ja) | 2016-08-03 |
Family
ID=42133705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Expired - Fee Related JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
| JP2014108085A Pending JP2014156484A (ja) | 2009-02-26 | 2014-05-26 | がん幹細胞を可視化・排除するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108085A Pending JP2014156484A (ja) | 2009-02-26 | 2014-05-26 | がん幹細胞を可視化・排除するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754035B2 (https=) |
| EP (1) | EP2400979B1 (https=) |
| JP (2) | JP5963443B2 (https=) |
| KR (1) | KR101672401B1 (https=) |
| CN (2) | CN106177954A (https=) |
| AU (1) | AU2010218261B2 (https=) |
| CA (1) | CA2753804C (https=) |
| IL (2) | IL214545A (https=) |
| WO (1) | WO2010099003A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648046B2 (en) * | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
| WO2011151405A1 (en) * | 2010-06-04 | 2011-12-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence |
| CA2896058A1 (en) | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| EP3157547A1 (en) * | 2014-06-18 | 2017-04-26 | Prorec Bio AB | Prolactin receptor antagonists for treatment of glioblastoma |
| CN107198779A (zh) * | 2016-11-29 | 2017-09-26 | 南京东纳生物科技有限公司 | 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| US20220362771A1 (en) * | 2018-07-13 | 2022-11-17 | Hifibio Sas | Use of droplet single cell epigenome profiling for patient stratification |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1055932A (en) | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
| DE2616086C2 (de) | 1976-04-13 | 1986-04-03 | Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg | Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin |
| ATE366114T1 (de) * | 1998-05-12 | 2007-07-15 | Greenville Hospital System | Verwendung von anti-prolaktin agentien zur behandlung von krebs |
| EP1240337B1 (en) * | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| AU2001259837A1 (en) | 2000-05-09 | 2001-11-20 | Greenville Hospital System | Therapeutic pore-forming peptides |
| JP2005504032A (ja) * | 2001-07-31 | 2005-02-10 | ファイザー・プロダクツ・インク | エストロゲン・アゴニスト／アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法 |
| WO2003082301A1 (en) * | 2002-03-29 | 2003-10-09 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| BR0314227A (pt) | 2002-09-11 | 2005-10-25 | Fresenius Kabi De Gmbh | Derivados de amido de hidroxialquila |
| GEP20084487B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
| US8754031B2 (en) * | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US20050238628A1 (en) * | 2004-04-08 | 2005-10-27 | Blau Carl A | Methods for treating cancer |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| WO2009089537A2 (en) * | 2008-01-11 | 2009-07-16 | Northwestern University | Anti-cancer compounds |
-
2010
- 2010-02-16 EP EP20100705493 patent/EP2400979B1/en not_active Not-in-force
- 2010-02-16 KR KR1020117022422A patent/KR101672401B1/ko not_active Expired - Fee Related
- 2010-02-16 US US12/706,702 patent/US8754035B2/en not_active Expired - Fee Related
- 2010-02-16 CN CN201610657107.2A patent/CN106177954A/zh active Pending
- 2010-02-16 CN CN2010800089960A patent/CN102341118A/zh active Pending
- 2010-02-16 WO PCT/US2010/024340 patent/WO2010099003A2/en not_active Ceased
- 2010-02-16 AU AU2010218261A patent/AU2010218261B2/en not_active Ceased
- 2010-02-16 JP JP2011552066A patent/JP5963443B2/ja not_active Expired - Fee Related
- 2010-02-16 CA CA2753804A patent/CA2753804C/en not_active Expired - Fee Related
-
2011
- 2011-08-09 IL IL214545A patent/IL214545A/en not_active IP Right Cessation
-
2014
- 2014-05-26 JP JP2014108085A patent/JP2014156484A/ja active Pending
-
2016
- 2016-06-15 IL IL246247A patent/IL246247A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519168A5 (https=) | ||
| US10918741B2 (en) | PSMA-targeting imaging agents | |
| Lu et al. | Ghrelin receptor as a novel imaging target for prostatic neoplasms | |
| Hernandez Vargas et al. | Specific targeting of somatostatin receptor subtype-2 for fluorescence-guided surgery | |
| Shaw et al. | High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors | |
| Soendergaard et al. | In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging | |
| Utsunomiya et al. | Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line | |
| JP5963443B2 (ja) | がん幹細胞を可視化・排除するための組成物および方法 | |
| CN110312517A (zh) | 促黄体激素释放激素受体(lhrh-r)缀合物及其用途 | |
| Liu et al. | 99mTc-labeled SWL specific peptide for targeting EphA2 receptor | |
| US9415122B2 (en) | Methods and compositions for the detection of cancer cells | |
| van Ginkel et al. | L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer | |
| EP3166967B1 (en) | Synthetic somatostatin receptor ligands | |
| Ji et al. | Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin αvβ3–Targeted Radiotracer 99mTc-3P-RGD2 99mTc-3P-RGD2: An Integrin αvβ3–Targeted Radiotracer to Monitor Linifanib Therapy | |
| Turkbey et al. | Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer | |
| Kim et al. | Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin | |
| JP2022025113A (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| Stahl et al. | Positron emission tomography as a tool for translational research in oncology | |
| Reilly et al. | Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical | |
| Yan et al. | 99mTc-HYNIC-MPG: a novel SPECT probe for targeting mutated EGFR | |
| Su et al. | Preparation and bioevaluation of [99m Tc] Tc-labeled A7R and D A7R for SPECT imaging of triple-negative breast cancer | |
| Kruse et al. | Imaging requirements for personalized medicine: the oncologists point of view | |
| CN114945388B (zh) | 用于成像和治疗的纤维蛋白结合化合物 | |
| Song et al. | Abnormal 131I uptake in a benign serous ovarian cystadenoma mimicking bladder physiological uptake | |
| US20240374763A1 (en) | Diagnosis and monitoring using extradomain-b fibronectin targeted probes |